Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study

Jean-Pierre Gangneux*, Eric Dannaoui*, Arnaud Fekkar, Charles-Edouard Luyt, Françoise Botteril, Nicolas De Prost, Jean-Marc Tadié, Florian Reizine, Sandrine Houzé, Jean-François Timsit, Xavier Iriart, Béatrice Riu-Poulenc, Saad Nseir, Florence Persat, Florent Wallet, Patrice Le Pape, Emmanuel Canet, Ana Novara, Melek Manai, Estelle Cateau, Arnaud W Thille, Sophie Brun, Yves Cohen, Alexandre Alanio, Bruno Mégarbane, Muriel Cornet, Nicolas Terzi, Lionel Lamhaut, Estelle Sabourin, Guillaume Desoubeaux, Stephan Ehrmann, Christophe Hennequin, Guillaume Voiriot, Gilles Nevez, Cécile Aubron, Valérie Letschermenn, Marion Blaize, Julien Mayaux, Antoine Monsel, Frédérique Boquet, Florence Robert-Gangneux, Yves Le Tulzo, Philippe Seguin, Hélène Guegan, Brice Autier, Matthieu Lesouhaitier, Romain Pelletier, Sorya Belaz, Christine Bonnal, Antoine Berry, Jordan Leroy, Nadine François, Jean-Christophe Richard, Sylvie Paulus, Laurent Argaud, Damien Dupont, Jean Menotti, Florent Mario, Marie Soulé, Carole Schwelbel, Cécile Garraud, Juliette Guitard, Solène Le Gal, Dorothée Quinio, Jeff Morcet, Bruno Laviolle, Jean-Ralph Zahar*, Marie-Elisabeth Bougnoux*

Summary

Background Patients with severe COVID-19 have emerged as a population at high risk of invasive fungal infections (IFIs). However, to our knowledge, the prevalence of IFIs has not yet been assessed in large populations of mechanically ventilated patients. We aimed to identify the prevalence, risk factors, and mortality associated with IFIs in mechanically ventilated patients with COVID-19 under intensive care.

Methods We performed a national, multicentre, observational cohort study in 18 French intensive care units (ICUs). We retrospectively and prospectively enrolled adult patients (aged ≥18 years) with RT-PCR-confirmed SARS-CoV-2 infection and requiring mechanical ventilation for acute respiratory distress syndrome, with all demographic and clinical and biological follow-up data anonymised and collected from electronic case report forms. Patients were systematically screened for respiratory fungal microorganisms once or twice a week during the period of mechanical ventilation up to ICU discharge. The primary outcome was the prevalence of IFIs in all eligible participants with a minimum of three microbiological samples screened during ICU admission, with proven or probable (pr/pb) COVID-19-associated pulmonary aspergillosis (CAPA) classified according to the recent ECMM/ISHAM definitions. Secondary outcomes were risk factors of pr/pb CAPA, ICU mortality between the pr/pb CAPA and non-pr/pb CAPA groups, and associations of pr/pb CAPA and related variables with ICU mortality, identified by regression models. The MYCOVID study is registered with ClinicalTrials.gov, NCT04368221.

Findings Between Feb 29 and July 9, 2020, we enrolled 565 mechanically ventilated patients with COVID-19. 509 patients with at least three screening samples were analysed (mean age 59·4 years [SD 12·5], 400 [79%] men). 128 (25%) patients had 138 episodes of pr/pb or possible IFIs. 76 (15%) patients fulfilled the criteria for pr/pb CAPA. According to multivariate analysis, age older than 62 years (odds ratio [OR] 2·34 [95% CI 1·39–3·92], p=0·0013), treatment with dexamethasone and anti-IL-6 (OR 2·71 [1·12–6·56], p=0·027), and long duration of mechanical ventilation (>14 days; OR 2·16 [1·14–4·09], p=0·019) were independently associated with pr/pb CAPA. 38 (7%) patients had one or more other pr/pb IFIs: 32 (6%) had candidaemia, six (1%) had invasive mucormycosis, and one (<1%) had invasive fusariosis. Multivariate analysis of associations with death, adjusted for candidaemia, for the 509 patients identified three significant factors: age older than 62 years (hazard ratio [HR] 1·71 [95% CI 1·39–2·09], p<0·0001), treatment with dexamethasone and anti-IL-6 (HR 2·71 [1·12–6·56], p=0·027), and long duration of mechanical ventilation (>14 days; OR 2·16 [1·14–4·09], p=0·019) were independently associated with pr/pb CAPA. 38 (7%) patients had one or more other pr/pb IFIs: 32 (6%) had candidaemia, six (1%) had invasive mucormycosis, and one (<1%) had invasive fusariosis. Multivariate analysis of associations with death, adjusted for candidaemia, for the 509 patients identified three significant factors: age older than 62 years (hazard ratio [HR] 1·71 [95% CI 1·39–2·09], p<0·0001), treatment with dexamethasone and anti-IL-6 (HR 2·71 [1·12–6·56], p=0·027), and long duration of mechanical ventilation (>14 days; OR 2·16 [1·14–4·09], p=0·019) were independently associated with pr/pb CAPA. At time of ICU discharge, survival curves showed that overall ICU mortality was significantly higher in patients with pr/pb CAPA than in those without, at 61·8% (95% CI 50·0–72·8) versus 32·1% (27·7–36·7; p<0·0001).

Interpretation This study shows the high prevalence of invasive pulmonary aspergillosis and candidaemia and high mortality associated with pr/pb CAPA in mechanically ventilated patients with COVID-19. These findings highlight the need for active surveillance of fungal pathogens in patients with severe COVID-19.

Funding Pfizer.

Copyright © 2021 Elsevier Ltd. All rights reserved.
Research in context

Evidence before this study
Patients with severe viral respiratory infection caused by influenza have been shown to be at high risk of acute respiratory distress syndrome (ARDS) and prone to develop invasive pulmonary aspergillosis (IPA). SARS-CoV-2 infection can also lead to severe ARDS, for which mechanical ventilation is required. Patients with COVID-19 might thus also be at risk of developing invasive fungal infections (IFIs), including invasive aspergillosis (ie, COVID-19-associated invasive aspergillosis; CAPA), for which consensus criteria for research and clinical guidance were published in The Lancet Infectious Diseases in 2020. We searched the PubMed database, using the terms “COVID-19” AND (“aspergillosis” OR “candidaemia” OR “fungal infections”), to find studies that investigated the prevalence and risk factors of fungal co-infections in patients with COVID-19 published between Nov 1, 2019, and Sept 30, 2020. Only small cohort studies and case-reports have been published and variable prevalence of IFI was reported. We identified no active surveillance studies that had evaluated the prevalence, risk factors, and outcomes of IFIs in a large, homogenous, high-risk population of patients with COVID-19 and acute respiratory distress syndrome or requiring mechanical ventilation in the intensive care unit (ICU).

Added value of this study
To our knowledge, this study included the largest cohort of patients to be systematically screened for IFIs, enrolling 565 mechanically ventilated patients with COVID-19 in the ICU. First, we found a high number of cases of proven or probable (pr/pb) IFIs (114 [22%] of 509 patients analysed). Second, IPA and candidaemia were the most frequent IFIs. The overall prevalence of pr/pb CAPA, based on the recently published case definition, was 15%, and 6% for candidaemia. Third, this study found a high mortality among patients with pr/pb CAPA, of 61.8% (95% CI 50.0–72.8), versus 22.1% (27.7–36.7) for the non-pr/pb CAPA group, and patients with pr/pb CAPA had an independently higher risk of death (hazard ratio 1.45 [95% CI 1.03–2.03]) than those without. Of note, a high mortality of 45.8% (95% CI 25.6–67.2) was also observed in 24 (5%) patients with non-bronchoalveolar lavage or bronchial or tracheal aspiration positive for Aspergillus spp and a compatible clinical context of aspergillosis, compared with non-CAPA patients. Finally, we found that the combination of dexamethasone and anti-interleukin-6 for SARS-CoV-2 infection was significantly associated with pr/pb CAPA (odds ratio 2.71 [95% CI 1.12–5.65]), which is a milestone with regard to the management of patients with COVID-19.

Implications of all the available evidence
The high prevalence and mortality associated with IFIs, particularly invasive aspergillosis and candidaemia, highlight the need for a high index of suspicion for patients with severe COVID-19 in the ICU, and an urgent necessity of implementing active surveillance. Further studies are required to establish whether early antifungal treatment or prophylaxis is needed in patients at high risk of IFIs.

Introduction
Fungal infections are known to be among the infectious complications related to the damage caused by viral pulmonary infections, particularly in patients admitted to intensive care units (ICUs) with severe acute respiratory distress syndrome (ARDS). Indeed, invasive pulmonary aspergillosis (IPA) is now a well known complication of the clinical course of critically ill patients with influenza.12 Patients with severe COVID-19 have also emerged as a population with a high risk of fungal infections.13 COVID-19 is associated with epithelial lung damage, lymphopenia, dysfunction of the cell immune response, and the use of broad spectrum antibiotics, dexamethasone, and immunosuppressive therapies.3 Thus, adhesion of Aspergillus spp spores (conidia) might be promoted by previous damage of the lungs due to SARS-CoV-2 infection and multiple risk factors could lead to tissue invasion after conidia germination.4,5

During the COVID-19 pandemic, several case series have been published that suggest an increased risk of IPA in patients with severe COVID-19 (ie, COVID-19-associated pulmonary aspergillosis; CAPA), with an estimated prevalence of less than 5% to greater than 30% depending on several factors, whereas the prevalence of candidaemia and other fungal infections remains poorly understood.5 However, the heterogeneity of monitoring protocols, diagnostic tools, and severity of COVID-19 cases in previous studies (all hospitalised patients, only patients in the ICU, or only patients in the ICU with ARDS) create difficulties in interpreting published data.

Only recently have specific criteria for the case definition and diagnosis of CAPA been published.6 Consensus recommendations are essential because patients who have been infected during the pandemic do not meet the usual criteria of the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group for invasive aspergillosis, as no host-related risk factors or specific clinical features are evident in COVID-19 patients with IPA.7 In addition, the more focused aspergillosis algorithm (AspICU) to diagnose IPA in critically ill patients does not include new diagnostic developments and appears to be ill-adapted to patients with COVID-19.8 Furthermore, the typical radiological features of aspergillosis might be difficult to assess in ARDS-associated COVID-19,9 highlighting the importance of a multidisciplinary approach for the diagnosis and management of IPA in patients with COVID-19.

The MYCOVID study sought to characterise the prevalence, risk factors, and outcome of invasive fungal infections (IFIs), including IPA and candidaemia, in...
mechanically ventilated patients with COVID-19 in the ICU, with use of standardised procedures.

Methods

Study design and participants
We performed a national, multicentre, observational cohort study in 18 participating university hospital ICUs across France (appendix p 5). Adult patients (aged ≥18 years) were eligible for enrolment if they had a diagnosis of SARS-CoV-2 infection confirmed by quantitative RT-PCR, and required mechanical ventilation for ARDS. ARDS was defined in accordance with international guidelines proposed by the consensual ARDS Definition Task Force.12 Patients were consecutively

| Demographic characteristics* | All patients (n=509) | Patients with IFI† (n=128) | Patients without IFI (n=381) | Univariate odds ratio (95% CI) | p value |
|-----------------------------|---------------------|-----------------------------|-----------------------------|-------------------------------|---------|
| Sex at birth (n=509)        |                     |                             |                             |                               |         |
| Female                      | 109 (21%)           | 24 (19%)                    | 85 (22%)                    | 1.20 (0.46–3.16)              | 0.71    |
| Male                        | 400 (79%)           | 104 (81%)                   | 296 (78%)                   |                               |         |
| Age, years (n=509)          | 59.4 (12.5)         | 62.0 (12.5)                 | 58.5 (12.4)                 | 1.02 (1.01–1.04)              | 0.0057  |
| Weight, kg (n=493)          | 86.9 (17.6)         | 83.8 (17.3)                 | 87.9 (17.6)                 | 0.99 (0.97–1.00)              | 0.026   |
| Height, cm (n=487)          | 172.4 (9.1)         | 171.5 (8.5)                 | 172.7 (9.3)                 | 0.99 (0.96–1.01)              | 0.22    |
| Body-mass index, kg/m² (n=487) | 29.3 (5.6)       | 28.4 (4.8)                  | 29.6 (5.9)                  | 0.96 (0.92–1.00)              | 0.042   |
| Baseline characteristics*   |                     |                             |                             |                               |         |
| Dyslipidaemia (n=509)       | 21 (4%)             | 6 (5%)                      | 15 (4%)                     | 1.20 (0.46–3.16)              | 0.71    |
| Diabetes (n=508)            | 167 (33%)           | 45 (35%)                    | 122 (32%)                   | 1.15 (0.75–1.75)              | 0.53    |
| Hypertension (n=507)        | 254 (50%)           | 67 (53%)                    | 187 (43%)                   | 1.15 (0.77–1.72)              | 0.49    |
| Chronic obstructive pulmonary disease (n=509) | 34 (7%)          | 12 (9%)                     | 22 (6%)                     | 1.69 (0.81–3.52)              | 0.16    |
| Asthma (n=509)              | 14 (3%)             | 6 (5%)                      | 8 (2%)                      | 2.29 (0.78–6.74)              | 0.13    |
| Lymphopenia (n=503)         | 323 (64%)           | 82 (64%)                    | 241 (63%)                   | 1.02 (0.67–1.55)              | 0.92    |
| Solid organ transplantation (n=509) | 35 (7%)        | 15 (12%)                    | 20 (5%)                     | 2.40 (1.39–4.83)              | 0.015   |
| Haematological malignancy (n=508) | 6 (1%)          | 0                           | 6 (2%)                      | 0.99 (0.03–3.12)              | 0.98    |
| Any immunosuppression (n=509) | 55 (11%)         | 21 (16%)                    | 34 (9%)                     | 2.00 (1.12–3.60)              | 0.020   |
| Treatments received for COVID-19* |                   |                             |                             |                               |         |
| Lopinavir–ritonavir (n=509) | 111 (22%)           | 23 (18%)                    | 88 (23%)                    | 0.73 (0.44–1.21)              | 0.23    |
| Remdesivir (n=509)          | 20 (4%)             | 4 (3%)                      | 16 (4%)                     | 0.74 (0.24–2.24)              | 0.59    |
| Oseltamivir (n=508)         | 40 (8%)             | 13 (10%)                    | 27 (7%)                     | 1.48 (0.74–2.96)              | 0.27    |
| Cefotaxime (n=509)          | 25 (5%)             | 6 (5%)                      | 19 (5%)                     | 0.94 (0.37–2.40)              | 0.89    |
| Azithromycin (n=509)        | 15 (3%)             | 5 (4%)                      | 10 (3%)                     | 1.51 (0.51–4.90)              | 0.46    |
| Hydroxychloroquine (n=508)  | 167 (33%)           | 35 (27%)                    | 132 (35%)                   | 0.71 (0.45–1.10)              | 0.12    |
| Dexamethasone and anti-IL-6 | 29 (6%)             | 14 (11%)                    | 15 (4%)                     | 3.00 (1.40–6.40)              | 0.045   |
| Dexamethasone (n=504)       | 202 (40%)           | 58 (46%)                    | 144 (38%)                   | 1.39 (0.92–2.08)              | 0.12    |
| Anti-IL-1 (n=508)           | 38 (8%)             | 18 (14%)                    | 20 (5%)                     | 2.93 (1.50–5.73)              | 0.0017  |
| Prone position (n=508)      | 16 (3%)             | 4 (3%)                      | 12 (3%)                     | 0.99 (0.31–3.12)              | 0.99    |
| Clinical course data*       |                     |                             |                             |                               |         |
| Duration of mechanical ventilation, days (n=508) | 27.1 (19.8)     | 31.2 (23.1)                 | 25.8 (18.3)                 | 1.01 (1.00–1.02)              | 0.0098  |
| Simplified Acute Physiology Score II at admission (n=485) | 441 (16.2)    | 476 (17.9)                  | 429 (15.4)                  | 1.02 (1.01–1.03)              | 0.0053  |
| SOFA at admission (n=398)   | 7.4 (3.9)           | 7.8 (3.7)                   | 7.3 (4.0)                   | 1.03 (0.98–1.09)              | 0.25    |
| SOFA at day 7 (n=366)       | 8.7 (4.2)           | 9.8 (3.9)                   | 8.2 (4.3)                   | 1.09 (1.04–1.16)              | 0.0014  |
| SOFA at day 15 (n=261)      | 8.5 (4.6)           | 9.3 (4.3)                   | 8.0 (4.7)                   | 1.06 (1.00–1.12)              | 0.041   |
| SOFA at discharge (n=285)   | 6.1 (6.0)           | 8.2 (6.2)                   | 5.2 (5.7)                   | 1.09 (1.04–1.13)              | 0.0001  |
| Death in intensive care unit (n=509) | 186 (37%)       | 71 (55%)                    | 115 (30%)                   | 2.88 (1.91–4.35)              | <0.0001 |

Data are n (%) or mean (SD). IFI=invasive fungal infection. IL=interleukin. SOFA=Sequential Organ Failure Assessment. *Participants with data available are shown for each variable. †Patients with proven, probable, or possible IFI.

Table 1: Demographic and baseline characteristics and clinical course data for the final analysis set
In each participating ICU, patients were systematically screened for respiratory fungal microorganisms once or twice a week during the period of mechanical ventilation up to ICU discharge, resulting in a minimum of three samples if discharge occurred after 15 days (appendix p 8). Respiratory samples included any combination of bronchoalveolar lavage, non-bronchoscopic lavage, tracheal aspiration, and bronchial aspiration. The local microbiological laboratory in each participating centre processed fungal cultures of the samples. Real-time quantitative PCR (qPCR) for Aspergillus spp, Pneumocystis jirovecii, and Mucorales was also performed on the same samples, either locally or following referral to a specialised laboratory. Other microbiology sampling and tests were performed according to the local ICU hospital standard of care. Specific blood biomarkers (qPCR for either Aspergillus spp or Mucorales, galactomannan, and 1,3-β-D-glucan antigenemia) were sought if respiratory samples were positive either for filamentous fungi or P. jirovecii. Demographic and clinical data, including underlying diseases, clinical severity scores (Simplified Acute Physiology Score [SAPS] II and Sequential Organ Failure Assessment [SOFA]), anti-COVID-19 treatments, laboratory data (lumphopenia, viral detection of herpes simplex virus type 1 [HSV-1] and cytomegalovirus [CMV], bacterial and fungal ventilator-associated pneumonia [VAP], and candidaemia), and antifungal treatments were recorded in the eCRF.

The local investigators were requested to classify patients as being colonised or infected with proven or putative IPA according to the AspICU classification being used at the time of the study, published by Blot and colleagues10 (modified to patients with COVID-19, assuming no other systems were available at the time of the study). The criteria used by local investigators were given in the eCRF to standardise the case definition between centres. Standardised definitions are described in the appendix (pp 1–2).

Table 2: Prevalence of infections and antifungal treatments

| Prevalence of infections                  | Prevalence or duration |
|-----------------------------------------|------------------------|
| CAPA*: pr/pb invasive aspergillosis     | 76 (15%)               |
| pr/pb invasive fungal infection other than pr/pb CAPA (one or more) | 38 (7%) |
| Candidemia                              | 32 (6%)                |
| Invasive mucormycosis                   | 6 (1%)                 |
| Invasive fusariosis                     | 1 (<1%)                |
| Bacterial ventilator-associated pneumonia (n=509) | 374 (73%) |
| Cytomegalovirus infection (n=491)†      | 49 (10%)               |
| Herpes simplex virus type 1 infection (n=491) | 76 (15%)               |
| Duration of antifungal treatment, days  |                        |
| Fluconazole (n=30)‡                     | 19.2 (20.4)            |
| Caspofungin (n=70)‡                     | 7.9 (9.1)              |
| Liposomal amphotericin B (n=34)‡        | 11.8 (27.5)            |
| Voriconazole (n=73)‡                    | 15.2 (16.1)            |
| Isavuconazole (n=15)‡                   | 12.3 (6.1)             |

Data are n (%) or mean (SD). CAPA=COVID-19-associated pulmonary aspergillosis. pr/pb=proven or probable. “CAPA status according to Koehler et al.” in addition, 24 (5%) of 509 patients with a compatible clinical context were positive for Aspergillus spp in non-bronchoalveolar lavage or bronchial or tracheal aspiration but did not meet the criteria for pr/pb CAPA; these were classified as possible IFIs. Some patients with pr/pb CAPA or possible CAPA also had other IFIs, thus 128 patients with pr/pb or possible IFIs had ≥1 IFI episodes overall. Number of patients receiving each treatment; denominator for each group (ie, patients with available data on antifungal treatments) was 162.

Outcomes

The primary outcome was the prevalence of IFIs. Secondary outcomes were risk factors of proven or probable (pr/pb) CAPA, ICU mortality between the pr/pb CAPA and non-pr/pb CAPA groups, and associations of pr/pb CAPA and related variables with ICU mortality, identified by regression modelling. To evaluate pr/pb CAPA, the primary criteria evaluated were the most recent definitions from the European Confederation of Medical Mycology and International Society for Human and Animal Mycology (ECMM/ISHAM) published by Koehler and colleagues.9 This classification is depicted in the appendix (pp 1–2); the final analysed populations of patients with and without pr/pb CAPA were based on the ECMM/ISHAM criteria. We also used the criteria for proven or putative IPA according to the AspICU algorithm (appendix pp 1–2).15 Candidaemia was defined as one or more positive blood cultures for Candida spp. For patients with a positive qPCR for P. jirovecii, the cycle threshold was recorded but it was not possible to discriminate between infection and colonisation because direct examination was not performed due to SARS-Cov-2-related hazards. The
Articles

Diagnosis of other IFIs was done on a case-by-case basis for respiratory or serum samples positive for other filamentous fungi. The full population for prevalence calculations and secondary analyses was defined as patients who did not oppose participation in the study, met the eligibility criteria, and were systematically screened for fungal respiratory microorganisms from study entry to discharge from the ICU with a minimum of three samples screened. The characteristics of patients with IFIs or pr/pb CAPA were compared to those without. Supplementary analyses of co-infections are ongoing and will be published at a later date.

Statistical analysis

Our objective was to enrol a minimum of 250 patients, thus allowing a precision of estimation (ie, 95% CI) between 6.3% and 13.7%-with 80% power if the percentage of positive patients was 10%. Continuous variables are presented as means, with SDs, and categorical variables as numbers and percentages. Univariate logistic regression analysis was also performed for some variables (relevant baseline and demographic variables, treatments, and clinical course) to identify parameters associated with IFIs (pr/pb CAPA in particular) and ICU mortality. Multivariate analysis with Cox regression or logistic regression models, via a stepwise regression with a forward selection method, was used to identify the parameters most associated with IFIs, pr/pb CAPA, and mortality, adjusted for candidemia for mortality regression. Receiver operating characteristic curves were used to confirm variable cutoffs (eg, for age). As CAPA prevalence was not collected at baseline, in multivariate Cox analysis, landmark analysis was also performed, in which landmark time was the mean of the delay of CAPA occurrence. Any treatments found to be significantly associated with pr/pb CAPA were analysed post-hoc in multivariate analyses for associations with other relevant factors. Survival curves were constructed with the Kaplan-Meier method and were compared via the log-rank test. Survival at ICU discharge was compared between the pr/pb CAPA and non-pr/pb CAPA groups, and, post hoc, between antifungal treatment and no treatment groups. Two-sided tests were used and considered statistically significant for p values less than 0.05. All statistical analyses were performed with SAS software (version 9.4). An independent data monitoring committee provided an external medical and statistical review of the data, in particular for verification of data entry and the management of missing data.

Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report, or in the decision to submit the paper for publication.

Results

Between Feb 29 and July 9, 2020, corresponding to the first wave of COVID-19, 576 mechanically ventilated patients with COVID-19 were screened and 565 were enrolled in the MYCOVID study, with 465 (82%) enrolments between March 15 and April 15, 2020. 509 patients were included in the final analysis, after 56 did not undergo complete mycological screening.
The mean duration of stay in the ICU was 32.7 days (24-1). The baseline characteristics of the 509 patients included in the statistical analysis, and variables associated with IFIs, are shown in table 1. Mean age was 59.4 years (12.5) and 400 (79%) patients were men. Mean body-mass index was 29.3 kg/m² (5.6). Baseline characteristics and comorbidities were typical of COVID-19, with 167 (33%) patients (n=508 with available data) presenting with diabetes, 254 (50%; n=507) with hypertension, and 323 (64%; n=503) with lymphopenia according to local thresholds. The mean duration of mechanical ventilation was 27.1 days (19.8; n=508) and 186 (37%) of 509 patients died in the ICU. In total, 128 (25%) patients had 138 episodes of pr/pb or possible IFIs.

According to the ECMM/ISHAM CAPA definitions, all 509 patients fulfilled the criteria of pr/pb CAPA (appendix pp 1-2). According to the AspICU classification that was available at the time of the study, 57 (11%) patients were classified by local investigators as having putative IPA and 48 (9%) as being colonised. In the cohort, 24 (5%) patients of 509 patients with a compatible clinical context of aspergillosis had samples that were positive for *Aspergillus* spp in non-bronchoscopic lavage, bronchial aspiration, or tracheal aspiration, but these episodes did not meet the criteria for pr/pb CAPA and were classified as possible IFI (non-pr/pb CAPA for the main analysis). 38 (7%) patients had other types of pr/pb IFI, sometimes with co-infections with one or two different fungi (n=10 patients), consisting of 32 (6%) cases of candidaemia, six (1%) of invasive mucormycosis, and one (<1%) of invasive fusariosis. Thrus, overall, we recorded 114 (22%) cases of pr/pb IFI (76 pr/pb CAPA and 38 other IFIs). Among the six patients with mucormycosis, three had fungal co-infection (two had CAPA and one candidaemia). Additionally, six patients had CAPA and candidaemia and one patient had CAPA, candidaemia, and fusariosis. Four patients had a positive PCR test for *Pneumocystis jirovecii* that could be classified either as infection or colonisation, although invasive status was undetermined. Aside from fungal infections, 374 (73%) patients were diagnosed with bacterial VAP, 76 (15%) with a HSV-1 viral infection, and 49 (10%) with a CMV infection (table 2). Overall, 162 (32%) patients received antifungal treatment during the mechanical ventilation period. Among them, 58 received more than one antifungal. Voriconazole and caspofungin were the two most frequently administered antifungal drugs (table 2). When comparing patients with pr/pb or possible CAPA to non-CAPA patients, the main significant differences among overall characteristics were the mean age and weight of patients, treatment with dexamethasone combined with anti-interleukin (IL)-6 or anti-IL-6 alone, duration of mechanical ventilation, SAPS II score at admission, and SOFA score at discharge in univariate analysis (appendix pp 3-4).

IPA according to modified AspICU criteria declared by the local investigators was diagnosed at a mean of 11.5 days (11-5) and a median of 8-0 days (IQR 4-0-14-0) after ICU admission. We used the case definition of ECMM/ISHAM CAPA according to Koehler and colleagues in all subsequent analyses. We analysed the risk factors of pr/pb CAPA and effect of pr/pb CAPA on mortality. In univariate analysis, a main significant difference among overall characteristics between the group with pr/pb CAPA and the group without pr/pb CAPA was the mean age of patients (table 3). Other differences were the frequency of dexamethasone and anti-IL-6 administration (although marginally non-significant at p=0.055), the frequency of asthma, and clinical severity scores, with significantly higher SOFA scores for the pr/pb CAPA group than the non-pr/pb CAPA group at day 7, day 15, and discharge (table 3). According to multivariate analysis, three factors were independently associated with pr/pb CAPA: age older than 62 years (odds ratio [OR] 2.34 [95% CI 1.39-3.92], p=0.0013), treatment with dexamethasone combined with anti-IL-6 (OR 2.71 [1.12-6.56], p=0.027), and a longer duration of mechanical ventilation (>14 days; OR 2.16 [1.14-4.09], p=0.019; figure 1).

In univariate analysis, the mean duration of mechanical ventilation was significantly longer in patients with pr/pb CAPA at 31.8 days (25-8), versus 26.3 (18-4) for patients without pr/pb CAPA (table 3). At time of ICU discharge, survival curves showed that overall ICU mortality was significantly different between the two groups, at 32-1% (95% CI 27.7-36.7) for the non-pr/pb CAPA group versus 61-8% (50.0-72.8) for the pr/pb CAPA group (p<0.0001; figure 2). 58 (76%) of 76 patients with pr/pb CAPA received at least one antifungal drug, with 29 receiving more than one type. Among these patients, 44 (76%) received voriconazole, 20 (34%) received liposomal amphotericin B, 16 (28%) received caspofungin, 11 (19%) received isavuconazole, 30 (52%) received fluconazole, and 38 other IFIs. Among the six patients with mucormycosis, three had fungal co-infection (two had CAPA and one candidaemia). Additionally, six patients had CAPA and candidaemia and one patient had CAPA, candidaemia, and fusariosis. Four patients had a positive PCR test for *Pneumocystis jirovecii* that could be classified either as infection or colonisation, although invasive status was undetermined. Aside from fungal infections, 374 (73%) patients were diagnosed with bacterial VAP, 76 (15%) with an HSV-1 viral infection, and 49 (10%) with a CMV infection (table 2). Overall, 162 (32%) patients received antifungal treatment during the mechanical ventilation period. Among them, 58 received more than one antifungal. Voriconazole and caspofungin were the two most frequently administered antifungal drugs (table 2). When comparing patients with pr/pb or possible CAPA to non-CAPA patients, the main significant differences among overall characteristics were the mean age and weight of patients, treatment

### Table 1: Baseline Characteristics of the 509 Patients

| Characteristic                          | pr/pb CAPA (n=517) | Non-pr/pb CAPA (n=508) | p value  |
|----------------------------------------|--------------------|------------------------|---------|
| Mean age (years)                       | 61.1 (12.5)        | 59.4 (12.5)            | 0.0013  |
| Mean weight (kg)                       | 82.5 (19.8)        | 80.3 (19.8)            | 0.019   |
| Mean body-mass index (kg/m²)           | 29.3 (5.6)         | 28.1 (5.6)             | 0.0013  |

### Figure 1: Multivariate analysis of factors associated with pr/pb CAPA

All significant variables in univariate analysis were included in the multivariate model, but only significant variables in the multivariate analysis are shown in the figure. CAPA=COVID-19-associated pulmonary aspergillosis. pr/pb=proven or probable.
### Demographic characteristics

| Characteristics         | Death in the ICU (n=186) | Survival (n=323) | Univariate odds ratio (95% CI) | p value |
|-------------------------|--------------------------|------------------|--------------------------------|---------|
| Sex at birth            |                          |                  |                                |         |
| Female                  | 34 (18%)                 | 75 (23%)         | 1.07 (0.44-2.64)               | 0.88    |
| Male                    | 152 (82%)                | 248 (77%)        | 1.35 (0.86-2.06)               | 0.19    |
| Age, years              | 62.3 (10.9)              | 57.6 (13.1)      | 1.03 (1.01-1.05)               | 0.0001  |
| Weight, kg              | 86.8 (17.8)              | 86.8 (17.5)      | 1.00 (0.99-1.01)               | 0.93    |
| Body-mass index, kg/m²  | 29.2 (5.6)               | 29.3 (5.7)       | 0.99 (0.96-1.03)               | 0.73    |

### Baseline characteristics

| Characteristics         | Death in the ICU (n=186) | Survival (n=323) | Univariate odds ratio (95% CI) | p value |
|-------------------------|--------------------------|------------------|--------------------------------|---------|
| Dyslipidaemia           | 8 (4%)                   | 13 (4%)          | 2.37 (0.81-6.95)               | 0.11    |
| Diabetes                | 61 (33%)                 | 106 (33%)        | 1.33 (0.92-1.91)               | 0.13    |
| Hypertension            | 101 (55%)                | 153 (47.5)       | 1.81 (1.30-2.54)               | 0.10    |
| Chronic obstructive pulmonary disease | 17 (9%) | 17 (5%) | 0.86 (0.29-2.57) | 0.79 |
| Asthma                  | 8 (4%)                   | 6 (2%)           | 2.37 (0.81-6.95)               | 0.12    |
| Lymphopenia             | 127 (69%)                | 196 (62%)        | 1.36 (0.93-2.00)               | 0.11    |
| Solid organ transplantation | 22 (12%) | 33 (4%) | 3.16 (1.57-6.51) | 0.0014 |
| Haematological malignancy | 3 (2%)                  | 3 (1%)           | 1.76 (0.35-8.8)                | 0.49    |
| Any immunosuppression   | 28 (15%)                 | 27 (8%)          | 1.94 (1.11-3.41)               | 0.020   |

### Treatments received for COVID-19

| Treatment                | Death in the ICU (n=186) | Survival (n=323) | Univariate odds ratio (95% CI) | p value |
|--------------------------|--------------------------|------------------|--------------------------------|---------|
| Hydroxychloroquine       | 51 (27%)                 | 116 (36%)        | 0.67 (0.45-0.99)               | 0.047   |
| Oseltamivir              | 20 (11%)                 | 20 (6%)          | 1.82 (0.95-3.48)               | 0.070   |
| Cefotaxime               | 1 (1%)                   | 24 (7%)          | 0.07 (0.01-0.50)               | 0.0005  |
| Lopinavir-ritonavir      | 50 (27%)                 | 61 (19%)         | 1.58 (1.03-2.42)               | 0.036   |
| Remdesivir               | 7 (4%)                   | 13 (4%)          | 0.93 (0.37-2.38)               | 0.88    |
| Spiramycin               | 5 (3%)                   | 10 (3%)          | 0.86 (0.29-2.57)               | 0.79    |
| Azithromycin             | 3 (2%)                   | 7 (2%)           | 0.74 (0.19-2.90)               | 0.67    |
| Anti-ili-6               | 15 (8%)                  | 14 (4%)          | 0.94 (0.91-4.13)               | 0.085   |

Figure 2: Probability of survival according to pr/pb CAPA status

Shading shows 95% CIs. No patients were censored. Data were missing for one patient in the non-pr/pb CAPA group. pr/pb-proven or probable. CAPA=COVID-19-associated pulmonary aspergillosis.

and five (9%) received other antifungal drugs (unspecified), alone or in combination.

SAPS II and SOFA scores showed significant associations with death in the ICU in univariate analysis (table 4). Additionally, three demographic characteristics were significantly associated with overall mortality in the ICU: increased age, immunosuppression, and, in particular, solid organ transplantation (table 4). Among the treatments and management measures administered in the ICU to the patient population, the lopinavir–ritonavir combination and anti-IL-1 were each associated with death in the ICU, whereas, ceftaxime and hydroxychloroquine were associated with survival, although these findings were based on small numbers (table 4). The duration of mechanical ventilation was longer for patients who survived (mean 28.9 days [21.2]) than for those who died (24.1 days [16.6]; table 4). Other treatment or management measures showed no significant associations with mortality in the ICU (table 4).

Among secondary infections, only fungal co-infections (pulmonary aspergillosis) were significantly associated with death. In addition to the survival curves showing mortality to be significantly increased for patients with pr/pb CAPA (figure 2), pr/pb CAPA was associated with death in the univariate analysis (table 4). Notably, a high mortality of 45.8% (95% CI 25.6–67.2) was also observed in the 24 patients with non-bronchoalveolar lavage or bronchial or tracheal aspiration positive for Aspergillus spp and a compatible clinical context of aspergillosis, compared with non-CAPA patients (appendix p 10). The detection of Aspergillus spp in respiratory samples by culture or qPCR was also associated with death (33 of 186 patients who died with positive culture samples vs 30 of 323 patients who survived, OR 2.11 [1.24–3.59], p=0.0060; and 37 of 186 patients who died with positive qPCR vs 43 of 323 patients who survived, OR 1.62 [1.00–2.62], p=0.0051, data not shown), regardless of aspergillosis status. The introduction of an anti-Aspergillus spp triazole (voriconazole, isavuconazole, or both drugs) did not modify mortality (appendix p 11), nor did other antifungal drugs improve survival (data not shown).

Aside from invasive Aspergillus infections, among the other fungal co-infections, only candidaemia was associated with mortality (table 4) by univariate analysis. We subsequently performed a multivariate analysis of factors associated with death, which identified three significant factors: age older than 62 years (HR 1.49 [95% CI 1.06–2.09], p=0.021), solid organ transplantation (HR 2.16 [95% CI 1.24–3.72], p=0.0054), and pr/pb CAPA (HR 1.78 [95% CI 1.24–2.57], p=0.0020).
Multivariate analysis comparing patients with pr/pb CAPA to those without non-pr/pb CAPA revealed that treatment with dexamethasone and anti-IL-6 was independently associated with pr/pb CAPA (figure 1). 29 patients received a combination of dexamethasone and anti-IL-6 and were independently associated with CAPA (figure 1). Among these patients, eight (28%) were in the pr/pb CAPA group versus 21 (72%) in the non-pr/pb CAPA group (table 5). The association of other factors with dexamethasone and anti-IL-6 treatment are summarised in table 5. pr/pb CAPA was significantly associated with dexamethasone and anti-IL-6 treatment in multivariate analysis (OR 2.54 [1.00–6.43], p=0.0049).

Discussion
To our knowledge, MYCOVID is the largest cohort study to date to investigate the prevalence of IFIs due to filamentous fungi and yeasts among mechanically ventilated ICU patients infected with SARS-CoV-2, with assessment of the associated mortality and risk factors for such secondary infections. Among the homogeneous population of 509 patients, we recorded 114 (22%) episodes of pr/pb IFI (76 pr/pb CAPA and 38 other IFIs), which increased to 138 episodes when including patients with non-bronchoalveolar lavage or bronchial or tracheal aspiration positive for Aspergillus spp and a compatible clinical context of aspergillosis. The high prevalence observed in this study might be related to several factors, such as the homogeneous population of patients with severe COVID-19 and ARDS, the rigorous monitoring dedicated to fungal diagnosis, the role of previous comorbidities, and the role of the treatment received. pr/pb CAPA was the most prevalent fungal infection in this cohort. Most published data have represented heterogeneous COVID-19 populations and mainly used the AspICU case definitions. We used the recent ECMM/ISHAM CAPA definitions and identified a high prevalence. Indeed, pr/pb CAPA was identified in 76 (15%) patients, which provides an update on previous estimates of CAPA prevalence among mechanically ventilated patients with COVID-19. Highly variable IPA prevalence estimates, ranging from 2% to 28%, have been reported in 10 other studies that each included more than 80 patients with severe COVID-19. Such varying prevalence might be related to use of more or less stringent definitions of IPA and the monocentric nature of most of the studies, associated with variable local environmental risk and low numbers of patients (<150) included in eight of the studies.

We identified several factors associated with pr/pb CAPA by multivariate analysis. Patients with pr/pb CAPA were significantly older and had more severe disease based on SOFA score than patients without pr/pb CAPA. pr/pb CAPA was also associated with a longer duration of mechanical ventilation. Furthermore, patients with pr/pb CAPA more frequently received the combination therapy of dexamethasone and anti-IL-6, which was independently associated with pr/pb CAPA in multivariate analysis. Notably, patients treated with this combination were significantly younger than untreated patients and showed similar severity at admission, and had a similar duration of mechanical ventilation prior to the occurrence of CAPA (table 5).

We show, for the first time, that the combination of two immunomodulators (dexamethasone and anti-IL-6) is...
Table 5: Univariate and multivariate analysis of factors associated with dexamethasone and anti-IL-6 combination treatment

| Variable                                         | Univariate OR (95% CI) | Multivariate OR (95% CI) |
|--------------------------------------------------|------------------------|--------------------------|
| Age, years                                       | 29; 51·2 (13·3)        | 480; 59·8 (12·3)         |
| Hypertension                                     | 28                     | 479                      |
| Yes                                              | 8 (29%)                | 246 (51%)                |
| No                                               | 20 (71%)               | 231 (49%)                |
| Solid organ transplantation                       | 29                     | 480                      |
| Yes                                              | 4 (14%)                | 31 (6%)                  |
| No                                               | 25 (86%)               | 442 (94%)                |
| Any immunosuppression                            | 29                     | 480                      |
| Yes                                              | 6 (21%)                | 49 (10%)                 |
| No                                               | 23 (79%)               | 431 (90%)                |
| Duration of mechanical ventilation, days         | 29; 31·7 (19·3)        | 479; 26·9 (19·8)         |
| Simplified Acute Physiology Score II at admission| 25; 44·4 (15·2)        | 460; 44·1 (16·3)         |
| Sequential Organ Failure Assessment at admission | 25; 7·8 (3·6)          | 373; 7·4 (4·0)           |
| Death in intensive care unit                     | 29                     | 480                      |
| Yes                                              | 15 (52%)               | 171 (36%)                |
| No                                               | 14 (48%)               | 309 (64%)                |
| Proven or probable CAPA                         | 29                     | 480                      |
| Yes                                              | 8 (28%)                | 68 (14%)                 |
| No                                               | 21 (72%)               | 412 (86%)                |
| Aspergillus spp in respiratory samples           | 29                     | 480                      |
| Yes                                              | 9 (31%)                | 54 (11%)                 |
| No                                               | 20 (69%)               | 426 (89%)                |
| pr/pb invasive fungal infection other than pr/pb CAPA | 29                     | 480                      |
| Yes                                              | 3 (10%)                | 35 (7%)                  |
| No                                               | 26 (90%)               | 445 (93%)                |
| Candidaemia                                       | 29                     | 480                      |
| Yes                                              | 3 (10%)                | 29 (6%)                  |
| No                                               | 26 (90%)               | 451 (94%)                |

Data are n, n (%), mean (SD), or n; mean (SD). All variables were analysed but only statistically significant variables or variables of interest are presented. IL=interleukin. OR=odds ratio. *p=0·0098. †p=0·054. ‡CAPA status according to Koehler et al. 

has evolved on the basis of results of clinical trials, and corticosteroids are now recommended and more frequently used. By contrast, the benefit–risk ratio of anti-IL-6 treatment needs to be carefully evaluated due to conflicting results concerning its use and clinical significance in patients with COVID-19. Our results prompt us to warn clinicians about the use of this combination therapy and the risks associated with the resulting immunosuppression.

Other risk factors might be linked to environmental exposure but were not investigated in this study. Indeed, many centres have modified their existing air treatment to protect health-care workers from aerosolisation by creating negative air pressure zones, which could potentially increase the risk of Aspergillus exposure. Furthermore, some patients were treated in delocalised ICUs without any air treatment. Future studies should focus on the need to control environmental risk and use of early antifungal prophylaxis for high-risk patients receiving mechanical ventilation and immunosuppression.

Certain other respiratory viruses, such as influenza, also predispose patients to IPA. In such patients, infection by respiratory viruses results in epithelial damage and disruption of normal ciliary clearance, aiding the invasion of pulmonary tissues by Aspergillus. Furthermore, NADPH-oxidase impairment is a recognised additional factor of pathogenicity during influenza infection. The prevalence of IPA in patients infected with SARS-CoV-2 appears to be similar to the known prevalence of IPA during severe seasonal influenza, despite the accumulation of numerous facilitating factors in patients with COVID-19, including leukopenia or lymphopenia, T-cell perturbations, and treatment with corticosteroids, anti-IL-1, and anti-IL-6. Importantly, the median time of onset of IPA in patients with COVID-19 in the present study was 8·0 days (IQR 4·0–14·0) after ICU admission, corresponding to later coinfection than in influenza patients, in whom it generally occurs only 3 days after ICU admission. These differences in time between ICU admission and onset of IPA might be due to differences in the pathophysiology of the two viral infections.

A main finding of this study is the significantly higher mortality of patients with pr/pb CAPA, supported by both univariate and multivariate analyses, reaching 61·8% (50·0–72·8) by the time of ICU discharge in patients with pr/pb CAPA versus 32·1% (27·7–36·7) in patients without. In the group of patients with non-bronchoalveolar lavage positive for Aspergillus spp and a compatible clinical context of aspergillosis, a high mortality of 45·8% [95% CI 25·6–67·2] was also observed. Considering the debate around case definition, we observed a similar mortality outcome using the AspICU classification for putative IPA (31 [54%] deaths among 57 participants), even for patients categorised as colonised (17 [35%] deaths among 48 participants; data not shown). Although many authors have suggested that the presence of Aspergillus in
respiratory specimens from SARS-CoV-2-infected patients is a manifestation of colonisation, we advocate using the CAPA definitions and considering any marker indicating the presence of *Aspergillus* as an indication to perform a BAL, as also suggested by Van Grootveld and colleagues. In the MYCOVID study, all positive pr/pb CAPA diagnoses obtained from respiratory or blood samples were significantly associated with increased mortality and should be considered to signal a possible diagnosis. Antifungal treatment with voriconazole or isavuconazole did not affect mortality in patients with pr/pb CAPA. However, a limitation of this study is that it was not designed to evaluate the efficacy of antifungal treatment. Nevertheless, the increased mortality in patients with pr/pb CAPA warrants consideration of early antifungal strategies, such as antifungal prophylaxis or a pre-emptive strategies for high-risk patients, including those receiving dexamethasone combined with anti-IL-6, as well as the implementation of air treatment measures. Another limitation of the study is that algorithms for COVID-19 treatment have changed substantially since the first wave and findings reported here might not be generalisable to further COVID-19 waves.

Aside from aspergillosis, the MYCOVID study highlights the high prevalence of other fungal infections, occurring in 38 (7%) of 509 patients, the most frequent being candidaemia in 32 (6%) patients. Several authors have noted a global increase in the incidence of candidaemia in patients with COVID-19, even candidaemia due to *Candida auris*, which is an emerging pathogen in healthcare settings. Among these reports, a recent review found an overall incidence of candidaemia in patients with COVID-19 ranging from 0.7% to 23.5%, of which most occurred in the ICU. The reasons for such an increased incidence in this specific population are as yet poorly understood. Patients with COVID-19 are exposed to multiple risk factors for candidaemia, such as antibiotic therapy, corticosteroids, immunosuppressive therapy, and long ICU stays. Several studies have suggested that direct disruption of the intestinal barrier caused by COVID-19 might be an additional risk factor for candidaemia. Indeed, enterocytes are infected by SARS-CoV-2, suggesting a possible link with *Candida* spp gut translocation. A recent pilot study found enrichment of the faecal mycobiome with *Candida* and *Aspergillus* spp during the hospitalisation of 30 patients with COVID-19, compared with control patients with community-acquired pneumonia or healthy individuals. However, further studies are required to establish whether such alterations can explain the observed increased incidence of candidaemia. The high number of deaths in patients with candidaemia in the MYCOVID study (18 [56%] deaths among 32 patients) warrants the analysis of risk factors and establishment of optimal management and prevention strategies for candidaemia in this context.

Contrary to aspergillosis and candidaemia, VAP and viral infections (CMV and HSV-1) were not associated with increased mortality in our study. However, although the diagnosis of VAP is well standardised, the same is not true for CMV and HSV-1 infections. Thus, excluding additional episodes of viral co-infections is not possible in our study and the data were based on individual reporting.

This study highlights the high prevalence and associated mortality of IPA and candidiasis in patients with ARDS-associated COVID-19. Antifungal drugs with high efficacy and low toxicity are available, along with non-invasive diagnostic tools, to allow the efficient management of IFIs. The high mortality associated with pr/pb CAPA indicates the importance of improving the management of this infectious complication. Overall, the present findings highlight the need for a high index of suspicion and the implementation of active surveillance. Further studies are required to establish whether early antifungal treatment or prophylaxis are needed if risk factors, such as those found in this study, are present.

**Contributors**

J-PG, ED, J-RZ, and M-EB conceived and designed the trial; accessed, verified, and oversaw analysis of the data; and wrote the manuscript. BL and JM contributed to the protocol design and statistical analysis of the data. All other authors contributed equally to the implementation of the study, inclusion of patients, and data collection. All authors had full access to all the data in the study and vouch for the accuracy and completeness of the data, data analyses, and interpretation and fidelity to the protocol. All authors critically reviewed and approved the final version and had final responsibility for the decision to submit for publication.

**Data sharing**

Data collected for the study, including deidentified individual participant data, a data dictionary defining each field in the set, and the statistical analysis plan will be made available to other researchers on request from the time of publication of this Article. Research proposals can be submitted to the corresponding authors (J-PG or M-EB).

**Declaration of interests**

J-PG reports personal fees from Gilead and grants and personal fees from Pfizer, outside of the submitted work. ED reports grants and non-financial support from Merck Sharp & Dohme and Gilead and non-financial support from Pfizer and Astellas, outside of the submitted work. C-EL reports personal fees from Carmat, Merck, BioMérieux, Brahms (part of Thermo Fisher Scientific), Bayer Healthcare, and Faron, outside of the submitted work. FraB reports grants from Astellas, personal fees from Merck Sharp & Dohme, and non-financial support from Pfizer, Merck Sharp & Dohme, and Astellas, outside of the submitted work. J-FT reports personal fees from Pfizer, Merck, Astellas, and Gilead, outside of the submitted work. FP reports non-financial support from Gilead and Pfizer, outside of the submitted work. EmC reports personal fees from Gilead, Baxter, and Sanofi-Genzyme, outside of the submitted work. AA reports personal fees from Pfizer and Gilead, outside of the submitted work. MC reports grants from Pfizer, outside of the submitted work. J-M reports non-financial support from Gilead, outside of the submitted work. SE reports grants, personal fees, and non-financial support from Aerogen and Fisher & Paykel, outside of the submitted work. GV reports personal fees from Merck, BioMérieux and grants from SOX Oxygène and Janssen, outside of the submitted work. J-RZ reports personal fees from Pfizer and Gilead, outside of the submitted work. JuM reports personal fees from Pfizer and Gilead, outside of the submitted work. AF reports personal fees and non-financial support from Pfizer and Astellas, outside of the submitted work. BL and JM contributed to the protocol design and statistical analysis of the data. All other authors contributed equally to the implementation of the study, inclusion of patients, and data collection. All authors had full access to all the data in the study and vouch for the accuracy and completeness of the data, data analyses, and interpretation and fidelity to the protocol. All authors critically reviewed and approved the final version and had final responsibility for the decision to submit for publication.

**Data sharing**

Data collected for the study, including deidentified individual participant data, a data dictionary defining each field in the set, and the statistical analysis plan will be made available to other researchers on request from the time of publication of this Article. Research proposals can be submitted to the corresponding authors (J-PG or M-EB).

**Declaration of interests**

J-PG reports personal fees from Gilead and grants and personal fees from Pfizer, outside of the submitted work. ED reports grants and non-financial support from Merck Sharp & Dohme and Gilead and non-financial support from Pfizer and Astellas, outside of the submitted work. C-EL reports personal fees from Carmat, Merck, BioMérieux, Brahms (part of Thermo Fisher Scientific), Bayer Healthcare, and Faron, outside of the submitted work. FraB reports grants from Astellas, personal fees from Merck Sharp & Dohme, and non-financial support from Pfizer, Merck Sharp & Dohme, and Astellas, outside of the submitted work. J-FT reports personal fees from Pfizer, Merck, Astellas, and Gilead, outside of the submitted work. FP reports non-financial support from Gilead and Pfizer, outside of the submitted work. EmC reports personal fees from Gilead, Baxter, and Sanofi-Genzyme, outside of the submitted work. AA reports personal fees from Pfizer and Gilead, outside of the submitted work. MC reports grants from Pfizer, outside of the submitted work. J-M reports non-financial support from Gilead, outside of the submitted work. SE reports grants, personal fees, and non-financial support from Aerogen and Fisher & Paykel, outside of the submitted work. GV reports personal fees from Merck, BioMérieux and grants from SOX Oxygène and Janssen, outside of the submitted work. J-RZ reports personal fees from Pfizer and Gilead, outside of the submitted work. JuM reports personal fees from Pfizer and Gilead, outside of the submitted work. AF reports personal fees and non-financial support from Pfizer and Astellas, outside of the submitted work. BL and JM contributed to the protocol design and statistical analysis of the data. All other authors contributed equally to the implementation of the study, inclusion of patients, and data collection. All authors had full access to all the data in the study and vouch for the accuracy and completeness of the data, data analyses, and interpretation and fidelity to the protocol. All authors critically reviewed and approved the final version and had final responsibility for the decision to submit for publication.

**Data sharing**

Data collected for the study, including deidentified individual participant data, a data dictionary defining each field in the set, and the statistical analysis plan will be made available to other researchers on request from the time of publication of this Article. Research proposals can be submitted to the corresponding authors (J-PG or M-EB).

**Declaration of interests**

J-PG reports personal fees from Gilead and grants and personal fees from Pfizer, outside of the submitted work. ED reports grants and non-financial support from Merck Sharp & Dohme and Gilead and non-financial support from Pfizer and Astellas, outside of the submitted work. C-EL reports personal fees from Carmat, Merck, BioMérieux, Brahms (part of Thermo Fisher Scientific), Bayer Healthcare, and Faron, outside of the submitted work. FraB reports grants from Astellas, personal fees from Merck Sharp & Dohme, and non-financial support from Pfizer, Merck Sharp & Dohme, and Astellas, outside of the submitted work. J-FT reports personal fees from Pfizer, Merck, Astellas, and Gilead, outside of the submitted work. FP reports non-financial support from Gilead and Pfizer, outside of the submitted work. EmC reports personal fees from Gilead, Baxter, and Sanoﬁ-Genzyme, outside of the submitted work. AA reports personal fees from Pfizer and Gilead, outside of the submitted work. MC reports grants from Pfizer, outside of the submitted work. J-M reports non-financial support from Gilead, outside of the submitted work. SE reports grants, personal fees, and non-financial support from Aerogen and Fisher & Paykel, outside of the submitted work. GV reports personal fees from Merck, BioMérieux and grants from SOX Oxygène and Janssen, outside of the submitted work. J-RZ reports personal fees from Pfizer and Gilead, outside of the submitted work. JuM reports personal fees from Pfizer and Gilead, outside of the submitted work. AF reports personal fees and non-financial support from Pfizer and Astellas, outside of the submitted work. BL and JM contributed to the protocol design and statistical analysis of the data. All other authors contributed equally to the implementation of the study, inclusion of patients, and data collection. All authors had full access to all the data in the study and vouch for the accuracy and completeness of the data, data analyses, and interpretation and fidelity to the protocol. All authors critically reviewed and approved the final version and had final responsibility for the decision to submit for publication.
the submitted work. M-EB reports grants from Pfizer during the conduct of the study; grants and non-financial support from Gilead and Pfizer; and non-financial support from Merck Sharp & Dohme outside of the submitted work. All other authors declare no competing interests.

Acknowledgments
We thank Pfizer for funding this study. This study was performed under the auspices of the French Society for Medical Mycology. We thank the volunteers who participated in this study and Marie Le Naou, Emilie Rolland, and Valérie Turnel from the Department of Research and Innovation at Rennes University Hospital. We also thank Alex Edelman & Associates for the English editing.

References
1 Schauwvlieghe AFAD, Rijnders BJ, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. *Lancet Respir Med* 2018; 6: 782–92.
2 Verweij PE, Rijnders BJ, Brüggermann RJM, et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. *Intensive Care Med* 2020; 46: 1524–35.
3 Bassetti M, Kollef MH, Timsit JF. Bacterial and fungal superinfections in critically ill patients with COVID-19. *Intensive Care Med* 2020; 46: 2071–74.
4 Lai CG, Yu WL. COVID-19 associated with pulmonary aspergillosis: a literature review. *J Microbiol Immunol Infect* 2021; 54: 46–53.
5 Apostolopoulos A, Esquer Garrigos Z, Vijayvargiya P, Lerner AH, Farmakiotis D. Invasive pulmonary aspergillosis in patients with SARS-CoV-2 infection: a systematic review of the literature. *Diagnostics (Basel)* 2020; 10: 807.
6 Arastehfar A, Carvalho A, van de Veerdonk FL, et al. COVID-19 associated pulmonary aspergillosis (CAPA)—from immunity to treatment. *J Fungi (Basel)* 2020: 6: 91.
7 Marr KA, Platt A, Tornheim JA, et al. Aspergillosis complicating severe coronavirus disease. *Emerg Infect Dis* 2021; 27: 18–25.
8 Kochler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECM/HIMSH consensus criteria for research and clinical guidance. *Lancet Infect Dis* 2021; 21: e149–62.
9 Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clin Infect Dis* 2020; 71: 1367–76.
10 Böt S, Taccone FS, Van den Abeele AM, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. *Am J Respir Crit Care Med* 2012; 186: 56–64.
11 Machado M, Valerio M, Álvarez-Uria A, et al. Invasive pulmonary aspergillosis in the COVID-19 era: an expected new entity. *Mycoses* 2021; 64: 132–43.
12 Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin definition. *JAMA* 2012; 307: 2526–33.
13 Bartoletti M, Pascale R, Crocca M, et al. Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study. *Clin Infect Dis* 2020; published online July 28. https://doi.org/10.1093/cid/ciaa1065.
14 Delièvre S, Dudognon E, Fodil S, et al. Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort. *Clin Microbiol Infect* 2020; 27: 790.e1–790.e5
15 Dupont D, Menotti J, Turc J, et al. Pulmonary aspergillosis in critically ill patients with coronavirus disease 2019 (COVID-19). *Med Mycol* 2021; 59: 110–14.
16 Fekkar A, Lampros A, Mayaux J, et al. Occurrence of invasive pulmonary fungal infections in patients with severe COVID-19 admitted to the ICU. *Am J Respir Crit Care Med* 2021; 203: 307–17.
17 Lamoth F, Glampedakis E, Boillat-Blanco N, Oddo M, Pagani JL. Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients. *Clin Microbiol Infect* 2020; 26: 1706–08.
18 Maes M, Higginson E, Pereira-Dias J, et al. Ventilator-associated pneumonia in critically ill patients with COVID-19. *Crit Care* 2021; 25: 23.
19 Razzaz K, Arrester R, Haudebourg AF, et al. Risks of ventilator-associated pneumonia and invasive pulmonary aspergillosis in patients with viral acute respiratory distress syndrome related or not to coronavirus 19 disease. *Crit Care* 2020; 24: 699.
20 Ripa M, Galli L, Poli A, et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. *Clin Microbiol Infect* 2021; 27: 451–57.
21 White PL, Dhillon R, Cordey A, et al. A national strategy to diagnose coronavirus disease 2019-associated invasive fungal disease in the intensive care unit. *Clin Infect Dis* 2021; 73: e134–44.
22 Permpalung N, Chiang TP, Massie AB, et al. Coronavirus disease 2019 associated pulmonary aspergillosis in mechanically ventilated patients. *Clin Infect Dis* 2021; published online March 9. https://doi.org/10.1093/cid/ciaa221.
23 Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. *N Engl J Med* 2020; 383: 2333–44.
24 RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* 2021; 397: 1637–45.
25 Lamoth F, Lewis RE, Walsh TJ, Kontoyiannis DP. Navigating the uncertainties of COVID-19 associated aspergillosis (CAPA): a comparison with influenza associated aspergillosis (IAPA). *J Infect Dis* 2021; published online March 26. https://doi.org/10.1093/infdis/jiaa163.
26 Van Grootveld R, Van Paassen J, de Boer MGJ, et al. Systematic screening for COVID-19 associated invasive aspergillosis in ICU patients by culture and PCR on tracheal aspirate. *Mycoses* 2021; 64: 641–50.
27 Nucci M, Barreirios G, Guimarães LF, Deriquehem VAS, Castreheiras AC, Nsuer SA. Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic. *Mycoses* 2021; 64: 152–56.
28 Prestel C, Anderson E, Forsberg K, et al. Candida auris outbreak in a COVID-19 specialty care unit—Florida, July—August 2020. *MMWR Morb Mortal Wkly Rep* 2021; 70: 56–57.
29 Mastrandelo A, Germinarino BN, Ferrante M, et al. Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls. *Clin Infect Dis* 2020; published online Oct 30. https://doi.org/10.1093/cid/ciaa1394.
30 Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. *Gastroenterology* 2020; 158: 1831–33.e3.
31 Zuo T, Zhan H, Zhang F, et al. Alterations in fecal fungal microbiome of patients with COVID-19 during time of hospitalization until discharge. *Gastroenterology* 2020; 159: 1302–10.e5.